Analysts Issue Forecasts for OTCMKTS:ZLDPF Q3 Earnings

Key Points

• William Blair projects Zealand Pharma A/S will post Q3 2025 earnings of ($1.23) per share, with a full-year estimate of ($2.19) per share.
• Zealand Pharma A/S reported $16.06 earnings per share for their most recent quarter, missing expectations by ($0.66) with revenues significantly lower than estimates.
• Multiple brokerages, including Wells Fargo and BNP Paribas, have upgraded Zealand Pharma A/S to a "strong-buy" rating, reflecting positive sentiment from analysts.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Investment analysts at William Blair issued their Q3 2025 earnings per share estimates for shares of Zealand Pharma A/S in a research report issued on Thursday, August 14th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($1.23) for the quarter. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share. William Blair also issued estimates for Zealand Pharma A/S's Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at $13.04 EPS, Q1 2026 earnings at ($1.55) EPS, Q3 2026 earnings at ($1.65) EPS, Q4 2026 earnings at ($1.69) EPS and FY2026 earnings at ($4.80) EPS.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%.The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion.

A number of other research analysts also recently weighed in on ZLDPF. Zacks Research downgraded Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. Finally, Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. Five research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy".

Zealand Pharma A/S Price Performance

Shares of ZLDPF stock remained flat at $61.00 on Monday. Zealand Pharma A/S has a 1-year low of $49.98 and a 1-year high of $136.76. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10. The firm has a market cap of $4.33 billion, a P/E ratio of 4.28 and a beta of 0.71. The company's 50-day moving average price is $57.26 and its two-hundred day moving average price is $70.28.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.